Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Phase 2

Terminated

Conditions: HIV-1 Infection

Interventions: Drug: BMS-986001
Drug: Placebo matching with BMS-986001
Drug: Lamivudine
Drug: Efavirenz
Drug: Tenofovir

First Posted Date: 2011-12-09

Last Posted Date: 2016-04-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 297

Registration Number: NCT01489046

Locations: 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇹🇭
Local Institution, Nontaburi, Thailand

and more 12 locations

A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: efavirenz
Drug: fenofibric acid 105 mg

First Posted Date: 2011-11-16

Last Posted Date: 2012-08-01

Lead Sponsor: Mutual Pharmaceutical Company, Inc.

Target Recruit Count: 30

Registration Number: NCT01472380

Locations: 🇺🇸
INC Research, Morgantown, West Virginia, United States

The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1

Phase 3

Completed

Conditions: HIV Infection

Interventions: Drug: Efavirenz

First Posted Date: 2011-10-13

Last Posted Date: 2013-05-13

Lead Sponsor: Kirby Institute

Target Recruit Count: 32

Registration Number: NCT01451333

Locations: 🇹🇭
Khon Kaen University, Khon Kaen, Thailand
🇩🇪
Medical Group Practice, Berlin, Germany
🇹🇭
HIVNAT Research Collaboration, Patumwan, Bangkok, Thailand

and more 2 locations

A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Lopinavir ritonavir
Drug: Atazanavir ritonavir
Drug: Efavirenz

First Posted Date: 2011-10-03

Last Posted Date: 2011-10-04

Lead Sponsor: Göteborg University

Target Recruit Count: 242

Registration Number: NCT01445223

Locations: 🇸🇪
Department of Infectious Diseases, Goteborg, Sweden

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

Phase 4

Completed

Conditions: HIV Infection

Interventions: Drug: Atripla (r)
Drug: Efavirenz
Drug: Truvada
Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDC
Drug: Isoniazid
Drug: Rifampin/isoniazid FDC

First Posted Date: 2011-06-27

Last Posted Date: 2024-10-14

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 851

Registration Number: NCT01380080

Locations: 🇮🇳
BJ Medical College CRS, Pune, Maharashtra, India
🇮🇳
YRG CARE Medical Ctr., VHS Chennai CRS, Rajiv Gandhi Salai Taramani, Chennai, India
🇭🇹
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port Au Prince, Haiti

and more 15 locations

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

Phase 4

Conditions: HIV

Interventions: Drug: darunavir ritonavir raltegravir
Drug: atripla

First Posted Date: 2011-04-28

Last Posted Date: 2011-04-28

Lead Sponsor: East Carolina University

Target Recruit Count: 40

Registration Number: NCT01343225

Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

Not Applicable

Terminated

Conditions: HIV

Interventions: Drug: Raltegravir
Drug: Efavirenz

First Posted Date: 2011-02-10

Last Posted Date: 2019-10-31

Lead Sponsor: University of California, San Diego

Target Recruit Count: 2

Registration Number: NCT01293123

Locations: 🇺🇸
UCSD Antiviral Research Center, San Diego, California, United States

The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)

Phase 3

Completed

Conditions: HIV Infection

Interventions: Drug: Efavirenz

First Posted Date: 2011-01-07

Last Posted Date: 2013-05-13

Lead Sponsor: Kirby Institute

Target Recruit Count: 40

Registration Number: NCT01271894

Locations: 🇿🇦
Desmond Tutu HIV Foundation, Cape Town, South Africa
🇬🇧
Chelsea and Westminister Hospital, London, United Kingdom
🇹🇭
Thai Red Cross-AIDS Research Centre, HIV-NAT Research Collaboration, Bangkok, Thailand

and more 1 locations

A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: HIV

Interventions: Drug: TMC278
Drug: Efavirenz

First Posted Date: 2010-12-31

Last Posted Date: 2013-09-04

Lead Sponsor: Tibotec, Inc

Target Recruit Count: 20

Registration Number: NCT01268839

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Phase 3

Completed

Conditions: Infection, Human Immunodeficiency Virus I

Interventions: Drug: Dolutegravir
Drug: Atripla
Drug: Abacavir/Lamivudine
Drug: Abacavir/Lamivudine Placebo
Drug: Atripla placebo
Drug: Dolutegravir placebo

First Posted Date: 2010-12-20

Last Posted Date: 2018-04-04

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 844

Registration Number: NCT01263015

Locations: 🇬🇧
GSK Investigational Site, Tooting, London, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy